Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis - 23/05/15
This article has been published in an issue click here to access
Summary |
Patients with ANCA-associated vasculitis (AAV) have an increased risk of premature death and organ failure. Treatment strategies with immune-suppressive drugs need to balance disease control and prevention of relapse against the risk of side effects in particular infection and malignancy. The longer-term outcome of patients with AAV who participated in several randomised controlled trials has been published in recent years. The results of these and other newer studies will be the focus of this review.
El texto completo de este artículo está disponible en PDF.Esquema
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.